bioAffinity Technologies, Inc. — Form 8-K
Filed July 22, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
bioAffinity Technologies announced a collaboration with Pictor, Inc. to develop and commercialize next-generation diagnostic tests for asthma and COPD by integrating bioAffinity's flow cytometry with Pictor's targeted proteomic platform. bioAffinity retains intellectual property for the tests; Pictor retains its existing IP and owns new inventions related to its proteomic platform. No financial terms, equity stake, or milestone payments are disclosed in the filing.
Why this rating
Partnership expands market (asthma/COPD therapeutics $92B→$155B by 2030) and reduces cost structure, but vague terms and no disclosed financial commitment limit near-term materiality for $22.6M company.
See more from July 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.